EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY 4.0

A multicentre study to determine the in vitro efficacy of flomoxef against extended-spectrum beta-lactamase producing Escherichia coli in Malaysia

Polly Soo Xi Yap, Chun Wie Chong iD, Sasheela Ponnampalavanar, Ramliza Ramli, Azian Harun, Tengku Zetty Maztura Tengku Jamaluddin, Anis Ahmed Khan, Soo Tein Ngoi iD, Yee Qing Lee, Min Yi Lau, Shiang Chiet Tan, Zhi Xian Kong und 15 weitere

PeerJ · 2023

DOI: 10.7717/peerj.16393 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift PeerJ, 2023. Verfasst von Polly Soo Xi Yap und 26 weiteren Autor:innen. Beteiligte Einrichtung: Jeffrey Cheah School of Medicine and Health Science, Monash University Malaysia, Bandar Sunway, Selangor, Malaysia. Hauptthemen laut MEDLINE: Escherichia coli Infections. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministry of Higher Education (Malaysia), Transdisciplinary Research Grant Scheme, TRGS, Shionogi Singapore Pte. Ltd.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The high burden of extended-spectrum beta-lactamase-producing (ESBL)-producing Enterobacterales worldwide, especially in the densely populated South East Asia poses a significant threat to the global transmission of antibiotic resistance. Molecular surveillance of ESBL-producing pathogens in this region is vital for understanding the local epidemiology, informing treatment choices, and addressing the regional and global implications of antibiotic resistance.

Methods

Therefore, an inventory surveillance of the ESBL- Escherichia coli (ESBL-EC) isolates responsible for infections in Malaysian hospitals was conducted. Additionally, the in vitro efficacy of flomoxef and other established antibiotics against ESBL-EC was evaluated.

Results

A total of 127 non-repetitive ESBL-EC strains isolated from clinical samples were collected during a multicentre study performed in five representative Malaysian hospitals. Of all the isolates, 33.9% were isolated from surgical site infections and 85.8% were hospital-acquired infections. High rates of resistance to cefotaxime (100%), cefepime (100%), aztreonam (100%) and trimethoprim-sulfamethoxazole (100%) were observed based on the broth microdilution test. Carbapenems remained the most effective antibiotics against the ESBL-EC, followed by flomoxef. Antibiotic resistance genes were identified by PCR. The bla CTX-M-1 was the most prevalent ESBL gene, with 28 isolates (22%) harbouring bla CTX-M-1 only, 27 isolates (21.3%) co-harbouring bla CTX-M-1 and bla TEM , and ten isolates (7.9%) co-harbouring bla CTX-M-1, bla TEM and bla SHV . A generalised linear model showed significant antibacterial activity of imipenem against different types of infection. Besides carbapenems, this study also demonstrated a satisfactory antibacterial activity of flomoxef (81.9%) on ESBL-EC, regardless of the types of ESBL genes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Escherichia coli InfectionsHumansAnti-Bacterial Agentsbeta-LactamasesCarbapenemsEscherichia coliMalaysiaCephalosporins

Stichwörter der Autor:innen

Antimicrobial resistanceEnterobacteralesEscherichia coliExtended-spectrum beta-lactamase (ESBL)FlomoxefSurgical site infection

Substanzen

Anti-Bacterial Agentsbeta-LactamasesCarbapenemsflomoxefCephalosporins

Autor:innen und Institutionen

  • Jeffrey Cheah School of Medicine and Health Science, Monash University Malaysia, Bandar Sunway, Selangor, Malaysia.
  • School of Pharmacy, Monash University Malaysia, Bandar Sunway, Selangor, Malaysia.
  • Department of Medicine, Faculty of Medicine, Universiti Malaya, Kuala Lumpur, Malaysia.
  • Department of Medical Microbiology and Immunology, Faculty of Medicine, Universiti Kebangsaan Malaysia, Kuala Lumpur, Kuala Lumpur, Malaysia.
  • Department of Medical Microbiology and Parasitology, School of Medical Sciences, Universiti Sains Malaysia, Health Campus, Kubang Kerian, Kelantan, Malaysia.
  • Hospital Universiti Sains Malaysia, Kubang Kerian, Kelantan, Malaysia.

ORCID-Profile: Chun Wie Chong, Soo Tein Ngoi, Kartini Abdul Jabar, Cindy Shuan Ju Teh

Förderung

  • Ministry of Higher Education (Malaysia), Transdisciplinary Research Grant Scheme, TRGS
  • Shionogi Singapore Pte. Ltd

Zitieren

APA

Yap, P. S. X., Chong, C. W., Ponnampalavanar, S., Ramli, R., Harun, A., Tengku Jamaluddin, T. Z. M., Ahmed Khan, A., Ngoi, S. T., Lee, Y. Q., Lau, M. Y., Tan, S. C., Kong, Z. X., Woon, J. J., Mak, S. T., Abdul Jabar, K., Karunakaran, R., Ismail, Z., Salleh, S. A., Md Noor, S. S., …, & Teh, C. S. J. (2023). A multicentre study to determine the in vitro efficacy of flomoxef against extended-spectrum beta-lactamase producing Escherichia coli in Malaysia. PeerJ. https://doi.org/10.7717/peerj.16393

Vancouver

Yap PSX, Chong CW, Ponnampalavanar S, Ramli R, Harun A, Tengku Jamaluddin TZM, et al. A multicentre study to determine the in vitro efficacy of flomoxef against extended-spectrum beta-lactamase producing Escherichia coli in Malaysia. PeerJ. 2023. doi:10.7717/peerj.16393

BibTeX
@article{Yap2023,
  author = {Yap, Polly Soo Xi and Chong, Chun Wie and Ponnampalavanar, Sasheela and Ramli, Ramliza and Harun, Azian and Tengku Jamaluddin, Tengku Zetty Maztura and Ahmed Khan, Anis and Ngoi, Soo Tein and Lee, Yee Qing and Lau, Min Yi and Tan, Shiang Chiet and Kong, Zhi Xian and Woon, Jia Jie and Mak, Siew Thong and Abdul Jabar, Kartini and Karunakaran, Rina and Ismail, Zalina and Salleh, Sharifah Azura and Md Noor, Siti Suraiya and Masri, Siti Norbaya and Mohd Taib, Niazlin and Jasni, Azmiza Syawani and Tee, Loong Hua and Leong, Kin Chong and Lim, Victor Kok Eow and Abu Bakar, Sazaly and Teh, Cindy Shuan Ju},
  title = {A multicentre study to determine the in vitro efficacy of flomoxef against extended-spectrum beta-lactamase producing Escherichia coli in Malaysia},
  journal = {PeerJ},
  year = {2023},
  doi = {10.7717/peerj.16393}
}
Kostenlos starten →